Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Mar 15, 2016; 8(3): 248-257
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.248

Table 3 Ongoing adjuvant trials

Trial	Registration No.	Treatment groups	Patients planned
ESPAC-4	ISRCTN96397434	Gem + capecitabine	732
		Gem
APACT	NCT01964430	Gem + nab-paclitaxel	800
		Gem
ACCORD24	NCT01526135	FOLFIRINOX	490
		Gem
RTOG-0848	NCT01013649	Gem + RCT (capecitabine or 5-FU)	950
		Gem
Algenpantucel Immunotherapy	NCT01072981	Gem ± RCT + Algenpantucel-I vaccine	722
		Gem ± RCT

5-FU: 5-flourouracil; RCT: Randomized controlled trial.

Citation: Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol 2016; 8(3): 248-257
URL: https://www.wjgnet.com/1948-5204/full/v8/i3/248.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i3.248

Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol 2016; 8(3): 248-257 [PMID: 26989460 DOI: 10.4251/wjgo.v8.i3.248]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.